Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

MidazolamÀ» ÀÌ¿ëÇÑ ÀǽÄÁøÁ¤½Ã flumazenilÀÇ Åõ¿©°æ·Î¿¡ µû¸¥ »ý¡ÈÄ ¹× Çൿ¾ç»óÀÇ ºñ±³ ¿¬±¸

A COMPARATIVE STUDY ON THE VITAL SIGN AND BEHAVIOR APPEARANCE DEPENDING ON THE ROUTE OF FLUMAZENIL ADMINISTRATION IN CONSCIOUS SEDATION BY MIDAZOLAM

´ëÇѼҾÆÄ¡°úÇÐȸÁö 2002³â 29±Ç 2È£ p.159 ~ 167
±èÇö½Ä, ÀÌâ¼·, ÀÌ»óÈ£,
¼Ò¼Ó »ó¼¼Á¤º¸
±èÇö½Ä (  ) - Á¶¼±´ëÇб³ Ä¡°ú´ëÇÐ ¼Ò¾ÆÄ¡°úÇб³½Ç,
ÀÌâ¼· (  ) - Á¶¼±´ëÇб³ Ä¡°ú´ëÇÐ ¼Ò¾ÆÄ¡°úÇб³½Ç,
ÀÌ»óÈ£ (  ) - Á¶¼±´ëÇб³ Ä¡°ú´ëÇÐ ¼Ò¾ÆÄ¡°úÇб³½Ç,

Abstract

º» ¿¬±¸ÀÇ ¸ñÀûÀº midazolamÀ» ÀÌ¿ëÇÑ ÀǽÄÁøÁ¤ ½Ã ±æÇ×Á¦ÀÎ flumazenilÀÇ Åõ¿©°æ·Î¿¡ µû¸¥ È¿°ú¿Í ¾ÈÀü¼ºÀ» Æò°¡Çϱâ À§ÇÔÀÌ´Ù. ¿¬±¸´ë»óÀ¸·Î´Â 22~24¼¼ÀÇ °Ç°­ÇÑ 15¸íÀÇ ÀÚ¿øÀÚ¸¦ ÀÌ¿ëÇÏ¿´À¸¸ç, ±×µéÀº midazolam 0.2§·£¯§¸À» ºñ°­³» ºÐ¹«ÇÏ¿© ÁøÁ¤ÇÏ¿´À¸¸ç midazolam Åõ¿© 40ºÐ ÈÄ ±æÇ×Á¦ÀÎ flumazenil 0.2§·À» Á¤¸Æ ³» Åõ¿© ¹× ºñ°­ ³» Åõ¿©ÇÏ¿´´Ù.
°¢ Åõ¿©°æ·ÎÀÇ ¾ÈÀü¼º°ú È¿°ú¸¦ Æò°¡Çϱâ À§ÇØ ´ÙÀ½°ú °°Àº °üÂûÀÌ ½Ç½ÃµÇ¾ú´Ù. ´ë»óÀÇ »ý¡Èĸ¦ °üÂûÇϱâ À§ÇØ puser oxymeter(Nellcor symphony N-3000, Nellcor Puritan CO., USA)À» ÀÌ¿ëÇÏ¿© SaO©ü ¹× ¸Æ¹Ú¼ö¸¦ °üÂûÇÏ¿´°í, ÀüÀÚÇ÷¾Ð°è(Heartcare 200. National CO., Japan)À» ÀÌ¿ëÇÏ¿© À̿ϱ⠼öÃà±â Ç÷¾ÐÀ» °üÂûÇÏ¿´´Ù. ¶ÇÇÑ ½ÇÇè´ë»óÀÇ ÁÖ°üÀû Æò°¡¸¦ À§ÇØ visual analogue scale(VAS)¸¦ ÀÌ¿ëÇÏ¿©, ÁøÁ¤, ¼ö¸é, ÇÇ·Î ±×¸®°í ŵµ¿¡ ´ëÇØ ÁÖ°üÀûÀÎ Æò°¡¸¦ ½Ç½ÃÇÏ¿´´Ù. ¸ðµç ´ë»óÀº ƯÀÌÇÒ ºÎÀÛ¿ë¾øÀÌ È¸º¹µÇ¾ú´Ù.
¿¬±¸°á°ú¸¦ ¿ä¾àÇÏ¸é ´ÙÀ½°ú °°´Ù.
1. ºñ°­³» ºÐ¹«µÈ flumazenilÀº Á¤¸Æ³» Åõ¿©µÈ flumazenil¿¡ ºñÇØ ºü¸¥ ȸº¹À» º¸¿´À¸³ª, °ðÀ̾î Á¤¸Æ³» Åõ¿©¿¡ ºñÇØ ±íÀº ¼ö¸é»óÅ¿¡ ºüÁ³´Ù.
2. ºñ°­³» Åõ¿©µÈ flumazenil ¹× Á¤¸Æ³» Åõ¿©µÈ °æ¿ì ¸ðµÎ ÁÖÀÇÇÒ ºÎÀÛ¿ë ¹× »ý¡ÈÄÀÇ ¾ÇÈ­´Â °üÂûµÇÁö ¾Ê¾Ò´Ù.
ȸº¹ÀÇ ¸ñÀûÀ¸·Î ºñ°­³» ºÐ¹«µÈ flumazenilÀÇ °á°ú·Î ¹ÌÈÄ¾î º¼ ¶§, midazolamÀ» ÀÌ¿ëÇÑ ÀǽÄÁøÁ¤½Ã flumazenilÀÇ ºñ°­³» ºÐ¹«¸¦ ÅëÇØ º¸´Ù ¾ÈÀüÇÏ°í, È¿°úÀûÀÎ ÀǽÄÀüÁ¤ÇÏ Ä¡°úÄ¡·á°¡ °¡´ÉÇϸ®¶ó »ç·áµÈ´Ù. ÇÏÁö¸¸, flumazenilÀÇ ÀûÀýÇÑ ¿ë·® ¹× È¿°ú¸¦ ¾Ë±âÀ§ÇØ, midazolam°ú flumazenilÀÇ Ç÷Àå³óµµ¸¦ Æò°¡ÇÏ´Â ¾à¹°µ¿·ÂÇÐÀû ¿¬±¸°¡ °è¼ÓµÇ¾î¾ß Çϸ®¶ó »ç·áµÈ´Ù.
The purpose of this study was to evaluate the efficacy and safety depending on the route of flumazenil, as an antagonist against midazolam. The subjects of this study were 15 volunteers of 22--24 years old. They were se-dated with midazolam 0.2mg/Kg intranasal spray, and then 40 minutes after midazolam adiministration, they were given flumazenil 0.2mg intranasal spray for their reversal.
For evaluation of the efficacy and safety of intranasal spray for flumazenil, they were monitored with pulseoxymeter(Nellcor symphony N-3000, Nellcor Puritan CO. USA) and electric sphygmomanometer (Heartcare 200, National CO. Japan), and were assessed themselves using visual analogue scale(VAS) for tranquilization, sleep, fatigue and attitude. All of these subjects were reduced completely without any undesired situations.
The results from this study can be summarized as follows
1. Nasaly administered flumazenil using spray device produced much more rapid reduction than intravenously administered flumazenil, but soon after fell in more deep sedated state than intravenously administered flumazenil.
2. There were no considerable side effects or bad influence on vital signs of both nasaly administered flumazenil and intravenously administered flumazenil.
These results suggested that the flumazenil administered nasaly using spray device for reversal, we could treat patients safely and effectively under conscious sedation using midazolam administration. But, We will have to research about its optimal dosages for flumazenil, used as intranasal spray for reversal agents against the midazolam by evaluating the blood plasma concentration of midazolam and flumazenil.

Å°¿öµå

Midazolam;Flumazenil;ºñ°­³» ºÐ¹«;Midazolam;Flumazenil;Intranasal spary

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

KCI